Price
No data yet.
Social Signal Score
Analyst Ratings
19 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Gaurav D. Shah
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 202
- Beta
- 0.49
- Country
- US
- Piotroski score
- 0 / 9 (Weak)
- Altman Z-score
- -2.40
Financials
Net Income
$-49.23MEBITDA
$-46.68MFree Cash Flow
$-39.20MEPS (diluted)
$-0.43Shares Outstanding (diluted)
113.65M+1584.5%Operating Expenses
$50.97MCash & Debt
$269.51MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-223.12M | $-2.01 |
| 2024 | $0.00 | $-258.75M | $-2.73 |
| 2023 | $0.00 | $-245.59M | $-2.92 |
| 2022 | $0.00 | $-221.86M | $-3.26 |
| 2021 | $0.00 | $-169.07M | $-2.68 |
| 2020 | $0.00 | $-146.67M | $-2.52 |
| 2019 | $0.00 | $-83.23M | $-1.70 |
| 2018 | $0.00 | $-74.52M | $-1.89 |
| 2017 | $0.00 | $-29.50M | $-4.36 |
| 2016 | $0.00 | $-42.85M | $-6.41 |
| 2015 | $0.00 | $-67.98M | $-10.29 |
| 2014 | $0.00 | $-9.53M | $-4.53 |
| 2013 | $0.00 | $-7.62M | $-3.62 |
| 2012 | $0.00 | $-6.06M | $-2.88 |
Valuation
RCKThas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90+0.00%Social Signal Score
Mentions (12)
- Newsbusinesswire.com·38d ago·Positive
Rocket Pharmaceuticals to Participate in Chardan's 10th Annual Healthcare Conference CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that the company will attend Chardan's 10th Annual Healthcare Conference. The company will participate in a panel on Tuesday, October 20, 2026, at 1…
View source ↗ - Newsproactiveinvestors.com·46d ago·Positive
Rocket Pharmaceuticals shares rise 4% after securing access to $150 million credit facility Rocket Pharmaceuticals (NASDAQ: RCKT) shares rose 4% on Wednesday after the biotechnology company secured access to up to $150 million under a credit facility with Hercules Capital. The facility strengthens Rocket's financial position and provides additional capital to support its pivotal Phase 2 study of RP-A501 for Danon disease and its broader cardiovascular pipeline.
View source ↗ - Newsbusinesswire.com·46d ago·Positive
…ase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, highlighted key findings and development milestones presented during its October 6 Danon disease investor webinar. The update outlined a defined path to completing the FDA-aligned pivotal Phase 2 trial…
View source ↗ - Newsseekingalpha.com·46d ago·Positive
Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript Rocket Pharmaceuticals, Inc. (RCKT) Discusses Danon Disease Program Update With Focus on RP-A501 Pivotal Trial and Preliminary Clinical Data Transcript
View source ↗ - Newsmarketbeat.com·47d ago·Positive
Rocket Pharmaceuticals Details RP-A501 Pivotal Plan After Safety Reset Rocket Pharmaceuticals NASDAQ: RCKT outlined updated clinical, regulatory and commercial plans for its investigational gene therapy RP-A501 in Danon disease, reporting longer-term Phase I findings, preliminary Phase II observations and an FDA-aligned pivotal study design.
View source ↗ - Newsbusinesswire.com·47d ago·Positive
…Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders, today announced that it has entered into a credit facility agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $150 million. The facility streng…
View source ↗ - Newszacks.com·67d ago·Positive
RCKT Aligns With FDA on Completing Phase II Study in Danon Disease Rocket Pharmaceuticals aligns with the FDA on key phase II study elements for RP-A501, advancing its Danon disease gene therapy program toward completion.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Rocket Pharmaceuticals, Inc. (RCKT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsseekingalpha.com·68d ago·Positive
Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript Rocket Pharmaceuticals, Inc. (RCKT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
View source ↗ - Newszacks.com·74d ago·Positive
Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue? Rocket Pharmaceuticals (RCKT) reported earnings 30 days ago. What's next for the stock?
View source ↗ - Newszacks.com·103d ago·Positive
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus RCKT records earnings growth in the second quarter. Kresladi launch preparations advance and RP-A501 safety findings support its next development steps.
View source ↗ - Newsbusinesswire.com·104d ago·Positive
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today reported financial and recent operational results for the second quarter ended June 30, 2026. “The second quarter of 2026 materially strengthened R
View source ↗
Earnings
Thu, Feb 25(in 3 months)
Consensus estimate $-0.39 per share
Typical surprise +5.1% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.43 vs $-0.40miss
- Mon, Aug 10$1.08 vs $0.86beat
- Thu, May 7$-0.42 vs $-0.41miss
- Thu, Feb 26$-0.38 vs $-0.42beat
- Thu, Nov 6$-0.45 vs $-0.48beat
- Thu, Aug 7$-0.59 vs $-0.57miss
Estimates and results for RCKT via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by RCKT officers and directors.
- Bought
- $69k
- Sold
- $1.1m
2 trades
33 trades
- Chaudhuri Sarbanisold
- Wilson Martinsold
- Wilson Martinsold
- Wilson Martinsold
- Shah Gauravsold
- Shah Gauravsold
- Wilson Martinsold
- Stevens Christopher Jamessold
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in RCKT.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
